MktsMarkets

Zevra Therapeutics, Inc.
NASDAQ: ZVRAKey statistics
ZVRA News
Stories mentioning ZVRA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | 20,783 | 20,354 | 16,935 | 20,782 | 19,545 | 16,125 | 16,208 | 12,604 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 52,146 | 9,315 | 4,143 | (71,039) | (5,362) | (15,416) | (27,306) | (23,795) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | 44,804 | 12,666 | (977.00) | 76,906 | (1,917) | (20,368) | (33,225) | (19,855) |
| Tax Provision | 6,914 | 501.00 | (433.00) | 2,199 | 1,182 | 15,371 | 0.00 | 70.00 |
| Net Income (Loss) | 37,890 | 12,165 | (544.00) | 74,707 | (3,099) | (35,739) | (33,225) | (19,925) |
| Earnings Per Share (Basic) | 0.62 | 0.22 | (0.01) | 1.24 | (0.06) | (0.77) | (0.69) | (0.48) |
| Earnings Per Share (Diluted) | 0.60 | 0.21 | (0.01) | 1.21 | (0.06) | (0.69) | (0.48) | |
| Weighted Average Shares Outstanding (Basic) | 58,406 | 55,311 | 55,952 | 54,781 | 54,096 | 46,251 | 47,809 | 41,899 |
| Weighted Average Shares Outstanding (Diluted) | 60,230 | 57,263 | 55,952 | 56,325 | 54,096 | 47,809 | 41,899 | |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ZVRA
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is a stock listed on the Nasdaq Stock Market under the ticker symbol ZVRA. It last traded at $10.16 (Oct 19, 2026, 4:00 PM ET), up 2.2% on the day. That gives Zevra Therapeutics a market capitalisation of $613.4M and a price-to-earnings ratio of 10.5.
Over the past 52 weeks ZVRA has traded between $8.01 and $15.04.
Net income for the quarter ended Mar 31, 2026 was $37.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | $37.9M |
| Dec 31, 2025 | — | $12.2M |
| Sep 30, 2025 | — | -$544.0K |
| Jun 30, 2025 | — | $74.7M |
From Zevra Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…